145 related articles for article (PubMed ID: 27135784)
1. Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia.
Souchet L; Levy V; Ouzegdouh M; Tamburini J; Delmer A; Dupuis J; Le Gouill S; Pégourié-Bandelier B; Tournilhac O; Boubaya M; Vargaftig J; Choquet S; Leblond V;
Am J Hematol; 2016 Aug; 91(8):782-6. PubMed ID: 27135784
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia.
Gavriatopoulou M; Kastritis E; Kyrtsonis MC; Vassilakopoulos TP; Roussou M; Fotiou D; Migkou M; Mpakiri M; Tasidou A; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Jun; 58(6):1506-1508. PubMed ID: 27724158
[No Abstract] [Full Text] [Related]
5. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Tamburini J; Lévy V; Chaleteix C; Fermand JP; Delmer A; Stalniewicz L; Morel P; Dreyfus F; Grange MJ; Christian B; Choquet S; Leblond V
Leukemia; 2005 Oct; 19(10):1831-4. PubMed ID: 16121217
[TBL] [Abstract][Full Text] [Related]
6. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
8. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
Peinert S; Tam CS; Prince HM; Scarlett J; Wolf MM; Januszewicz EH; Westerman D; Seymour JF
Leuk Lymphoma; 2010 Dec; 51(12):2188-97. PubMed ID: 20939696
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Dimopoulos MA; Trotman J; Tedeschi A; Matous JV; Macdonald D; Tam C; Tournilhac O; Ma S; Oriol A; Heffner LT; Shustik C; García-Sanz R; Cornell RF; de Larrea CF; Castillo JJ; Granell M; Kyrtsonis MC; Leblond V; Symeonidis A; Kastritis E; Singh P; Li J; Graef T; Bilotti E; Treon S; Buske C;
Lancet Oncol; 2017 Feb; 18(2):241-250. PubMed ID: 27956157
[TBL] [Abstract][Full Text] [Related]
11. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease.
Tedeschi A; Benevolo G; Varettoni M; Battista ML; Zinzani PL; Visco C; Meneghini V; Pioltelli P; Sacchi S; Ricci F; Nichelatti M; Zaja F; Lazzarino M; Vitolo U; Morra E
Cancer; 2012 Jan; 118(2):434-43. PubMed ID: 21732338
[TBL] [Abstract][Full Text] [Related]
14. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Leblond V; Ben-Othman T; Deconinck E; Taksin AL; Harousseau JL; Delgado MA; Delmer A; Maloisel F; Mariette X; Morel P; Clauvel JP; Duboisset P; Entezam S; Hermine O; Merlet M; Yakoub-Agha I; Guibon O; Caspard H; Fort N
J Clin Oncol; 1998 Jun; 16(6):2060-4. PubMed ID: 9626204
[TBL] [Abstract][Full Text] [Related]
15. Assessment of bone marrow response in Waldenström's macroglobulinemia.
Varghese AM; Rawstron AC; Ashcroft AJ; Moreton P; Owen RG
Clin Lymphoma Myeloma; 2009 Mar; 9(1):53-5. PubMed ID: 19362973
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease.
Leblond V; Lévy V; Maloisel F; Cazin B; Fermand JP; Harousseau JL; Remenieras L; Porcher R; Gardembas M; Marit G; Deconinck E; Desablens B; Guilhot F; Philippe G; Stamatoullas A; Guibon O;
Blood; 2001 Nov; 98(9):2640-4. PubMed ID: 11675332
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination.
Pilorge S; Park S; Dreyfus F; Bouscary D; Tamburini J
Leuk Lymphoma; 2010 Dec; 51(12):2288-90. PubMed ID: 20929331
[No Abstract] [Full Text] [Related]
18. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Dimopoulos MA; Hamilos G; Efstathiou E; Siapkaras I; Matsouka C; Gika D; Grigoraki V; Papadimitriou C; Mitsibounas D; Anagnostopoulos N
Leuk Lymphoma; 2003 Jun; 44(6):993-6. PubMed ID: 12854900
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Treon SP; Branagan AR; Ioakimidis L; Soumerai JD; Patterson CJ; Turnbull B; Wasi P; Emmanouilides C; Frankel SR; Lister A; Morel P; Matous J; Gregory SA; Kimby E
Blood; 2009 Apr; 113(16):3673-8. PubMed ID: 19015393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]